Analyst Expectations For Haemonetics's Future

4 analysts have expressed a variety of opinions on Haemonetics HAE over the past quarter, offering a diverse set of opinions from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $94.0, a high estimate of $105.00, and a low estimate of $84.00. Observing a downward trend, the current average is 11.6% lower than the prior average price target of $106.33.

Exploring Analyst Ratings: An In-Depth Overview

The perception of Haemonetics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Haemonetics. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Haemonetics compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Haemonetics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

For valuable insights into Haemonetics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Haemonetics analyst ratings.

All You Need to Know About Haemonetics

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Haemonetics: A Financial Overview

Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.

Revenue Growth: Haemonetics's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -3.7%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Haemonetics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 17.54%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Haemonetics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.71% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Haemonetics's ROA excels beyond industry benchmarks, reaching 2.33%. This signifies efficient management of assets and strong financial health.

Debt Management: Haemonetics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.49, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

Analyst Ratings: Simplified

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.